US 12648909 B1Patent grantUnited States

Calcium-Molybdate Cancer-Cell Screening Material

Official patent title

Method of treating cancer cells using CaMoO4/CaSiO3/g-C3N4 crystalline nanocomposite material

Arabic title: طريقة لعلاج الخلايا السرطانية باستخدام مادة نانو مركبة بلورية CaMoO4/CaSiO3/g-C3N4

Invention

Problem

Cancer treatment can be limited by toxicity, low selectivity, drug resistance, poor bioavailability, and nonspecific targeting, motivating laboratory investigation of new materials against cancer cells.

Why it matters

The disclosure concerns incubated cancer cells only, not treatment in animals or people. Selectivity, mechanism, dose response, normal-cell toxicity, biodistribution, clearance, in vivo efficacy, and clinical safety require independent verification.

Approach

The method incubates breast or liver cancer cells with a particulate CaMoO4/CaSiO3/g-C3N4 crystalline nanocomposite in an amount stated to induce apoptosis or kill at least 60% of the cells.

Who may benefit

Potential beneficiaries are preclinical cancer-biology laboratories, nanotoxicology researchers, pharmaceutical-formulation scientists, materials-characterization facilities, and technology-transfer teams evaluating early laboratory findings.

Potential value

The disclosure connects a defined porous three-phase nanocomposite with cell-incubation methods for specified breast and liver cancer cell types and a proposed pharmaceutical composition.

Background

Cancer remains difficult to treat because conventional chemotherapy can have cytotoxicity, low therapeutic indices, poor solubility or bioavailability, nonspecific distribution, high dose requirements, and acquired resistance. Nanomaterials are investigated as potential agents or delivery platforms because their size, shape, and surfaces can be modified. Those general possibilities do not establish safety or therapeutic benefit for a particular material. The publication therefore presents an early cell-incubation concept using a calcium-molybdate, calcium-silicate, and graphitic-carbon-nitride composite.

Technology overview

Claim 1 incubates breast or liver cancer cells with tetragonal CaMoO4, CaSiO3, and graphitic C3N4 in a particulate composite. It states a CaMoO4:CaSiO3:C3N4 weight ratio of about (0.8-1.2):(0.8-1.2):(0.8-1.2), substantially spherical oxide particles averaging about 5 to about 20 nm, mesoporous C3N4 nanosheets, a monomodal pore distribution, an average pore diameter of about 15 to about 25 nm, and BET surface area of about 60 to about 100 m2/g. Other claims identify breast and liver cell types and a pharmaceutical composition.

Potential applications

In vitro screening against specified breast cancer cells.
In vitro screening against specified liver cancer cells.
Preclinical mechanism, selectivity, formulation, and toxicology research.

Evidence-supported advantages

Defines three crystalline phases and their approximate weight relationship.
Specifies particle, pore, and surface-area characteristics.
States a cell-killing threshold for the disclosed incubation method.
Covers selected breast and liver cancer cells and a proposed composition.

Development stage

The patent publication describes incubation of cancer cells and states at least 60% cell killing; no animal or human study is disclosed, commercialization was not established, and the reported result and development stage were not independently verified.

Commercial opportunity

The appropriate opportunity is limited to preclinical research licensing or sponsored validation. Any therapeutic pathway would require reproducible cell-line data, normal-cell controls, mechanism and dose studies, formulation quality, sterility, biodistribution, toxicology, animal studies, manufacturing controls, and clinical evidence. No human efficacy, safety, or approval is established.

Patent classifications

WIPO IPC

A61K9/14Preparations for medical, dental or toiletry purposes
A61K33/06Preparations for medical, dental or toiletry purposes

CPC

A61K9/143Preparations for medical, dental or toiletry purposes
A61K33/06Preparations for medical, dental or toiletry purposes
A61K33/24Preparations for medical, dental or toiletry purposes
A61P35/00Specific therapeutic activity of chemical compounds or medicinal preparations

Inventors

First inventorMohamed Khairy Abdel Fattah Omran
InventorBabiker Yagoub Elhadi Abdulkhair

Keywords

cancer cells
in vitro
CaMoO4
CaSiO3
C3N4
apoptosis
breast cancer
liver cancer
nanocomposite

Patent document and drawings

The patent publication is mapped to this record. Patent drawings remain within that publication; no separately cleared public media package has been supplied.